During the 10th Giornata della Ricerca della Svizzera italiana (Research Day of the Italian-speaking part of Switzerland), which took place on June 25 at the Lugano East Campus, Ente Ospedaliero Cantonale (EOC) and UniversitÓ della Svizzera italiana (USI) officially presented the new EOC-USI Research Fund. The Fund’s mission is to support biomedical research to ensure effective, appropriate and efficient treatment, to support innovation and to enhance the results of research performed by researchers working at the two institutions.
The Fund was created in the context of the new "EOC-USI strategy for research in human medicine for 2021-2024", and is part of the USI Foundation for Research and Development. The ultimate purpose of Fund is to enable the EOC and USI to contribute - through basic medical, applied (translational), and clinical research - to improving the treatment and quality of life of people suffering from disease. For the EOC, research will be performed based on the needs of patients and through the teamwork of its doctors and researchers and a number of partners, in particular USI, with which it will pursue close collaborations on academic and public health subjects. Medical research will also be central to the academic training objectives of the USI Faculty of Biomedical Sciences.
The EOC-USI Fund is governed by a Board of experts from various fields who, on a voluntary basis, are responsible for strategically supporting excellent medical research for the community, and by an Evaluation Commission formed by representatives of the two institutions. The Commission is responsible for analysing and evaluating research projects, then advising the Board on the projects selected as priorities to be included in a funding portfolio. At the press conference held on 25 June three current examples of research projects were presented: one in cardiology aimed at preventing silent cerebral gas embolisms during cardiac surgery; one in internal medicine aimed at predicting hospital admission of patients with advanced chronic liver failure; and one in oncology aimed at understanding the different responses to inhibition of androgen receptor signalling in patients with metastatic prostate cancer.
For further information: www.fondoeoc-usi.org